Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00632736 · ClinicalTrials.gov registry record · Phase 3

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

A Phase 3 study of Parkinson Disease and Parkinson's Disease, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
419
Enrollment target
20
Study locations

NCT00632736 is a Phase 3 study of Parkinson Disease and Parkinson's Disease that has completed, run by GlaxoSmithKline. The registered enrollment target is 419 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00632736, a Phase 3 study of Parkinson Disease and Parkinson's Disease, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
419 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

Conditions Studied

Parkinson Disease Parkinson's Disease

Interventions

  • DRUG Ropinirole XL (formerly CR)

Study Locations (20)

Florida

  • GSK Investigational Site - Boca Raton
  • GSK Investigational Site - Panama City
  • GSK Investigational Site - Port Orange
  • GSK Investigational Site - St. Petersburg
  • GSK Investigational Site - Tampa

Michigan

  • GSK Investigational Site - Bingham Farms
  • GSK Investigational Site - Southfield
  • GSK Investigational Site - Traverse City

California

  • GSK Investigational Site - Fountain Valley
  • GSK Investigational Site - San Francisco

Georgia

  • GSK Investigational Site - Atlanta
  • GSK Investigational Site - Augusta

Alabama

  • GSK Investigational Site - Birmingham

Colorado

  • GSK Investigational Site - Englewood

Illinois

  • GSK Investigational Site - Glenview

Kansas

  • GSK Investigational Site - Kansas City

Trial Details

FieldValue
Enrollment Target 419 participants
Start Date 2004-02
Est. Completion 2010-03
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00632736

The ClinicalTrials.gov registry entry for NCT00632736 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Ropinirole XL (formerly CR) is the first listed.

NCT00632736 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Michigan, California.

Frequently Asked Questions

What is clinical trial NCT00632736 about?

NCT00632736 is a clinical study titled "An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease". To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

What is the current status of trial NCT00632736?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2004-02. Estimated completion is 2010-03.

What conditions does trial NCT00632736 study?

This clinical trial studies the following conditions: Parkinson Disease, Parkinson's Disease.

What interventions are being tested in trial NCT00632736?

The interventions under investigation include: Ropinirole XL (formerly CR) (DRUG).

Who is sponsoring clinical trial NCT00632736?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00632736 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.